500,000 Shares in Moderna, Inc. $MRNA Bought by Telemark Asset Management LLC

Telemark Asset Management LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 500,000 shares of the company’s stock, valued at approximately $12,915,000. Moderna makes up 1.2% of Telemark Asset Management LLC’s portfolio, making the stock its 27th biggest holding. Telemark Asset Management LLC owned about 0.13% of Moderna as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of Moderna in the first quarter valued at about $415,000. NewEdge Advisors LLC lifted its position in shares of Moderna by 732.7% during the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock valued at $328,000 after acquiring an additional 10,185 shares during the period. United Services Automobile Association purchased a new stake in shares of Moderna during the 1st quarter worth approximately $230,000. Focus Partners Wealth grew its holdings in shares of Moderna by 58.7% in the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock worth $668,000 after acquiring an additional 8,706 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in Moderna by 20.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 18,454 shares of the company’s stock valued at $529,000 after purchasing an additional 3,074 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on MRNA. Wolfe Research reissued an “underperform” rating and issued a $17.00 target price on shares of Moderna in a report on Thursday, November 20th. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a report on Monday, January 5th. UBS Group reiterated a “neutral” rating and issued a $36.00 price target on shares of Moderna in a research report on Monday, February 16th. Leerink Partners restated an “underperform” rating on shares of Moderna in a research report on Friday, January 30th. Finally, Bank of America lowered their target price on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a report on Monday, November 10th. Two research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average price target of $31.47.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA will review Moderna’s mRNA flu vaccine application after an initial refusal-to-file, with regulators now targeting a decision by Aug. 5, 2026 — a reversal that boosts the commercial outlook for a new recurring vaccine market and spurred an earlier jump in the stock. Moderna Stock Jumps After FDA Reverses Course on Flu Shot
• Positive Sentiment: Goldman Sachs analyst flagged upside for MRNA, an institutional vote of confidence that can support sentiment and buying interest. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna will present at TD Cowen and Barclays healthcare conferences in March — routine investor access that may provide more management detail but is unlikely by itself to move the stock dramatically. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech sued Moderna in Delaware federal court alleging Moderna’s mNexspike infringes a patent tied to BioNTech/Pfizer’s Comirnaty—new litigation increases legal risk, potential damages or injunctions, and heightens competitive/legal uncertainty for Moderna’s COVID-19/respiratory vaccine portfolio. BioNTech sues Moderna for patent infringement over COVID-19 shots
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in its patent dispute with Arbutus, representing another legal setback that could increase exposure and costs from long-running mRNA technology litigation. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Insider Buying and Selling at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the sale, the director directly owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This trade represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.90% of the stock is currently owned by insiders.

Moderna Stock Up 0.3%

MRNA stock opened at $49.87 on Friday. Moderna, Inc. has a one year low of $22.28 and a one year high of $55.20. The stock has a market capitalization of $19.49 billion, a P/E ratio of -6.86 and a beta of 1.32. The company has a 50 day moving average price of $39.02 and a two-hundred day moving average price of $30.47. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.79) by $0.68. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The business had revenue of $678.00 million for the quarter, compared to analysts’ expectations of $611.14 million. During the same quarter last year, the firm earned ($2.91) earnings per share. The business’s revenue was down 33.2% on a year-over-year basis. As a group, sell-side analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.